Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 2Thrombocythemia, Essential 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Mast-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 69fludarabine phosphate 63Busulfan 45Peripheral Blood Stem Cell Transplantation 42Tacrolimus 40Mycophenolic Acid 37Filgrastim 35Antilymphocyte Serum 35fludarabine 31Cyclosporine 30Radiotherapy 29Melphalan 29Whole-Body Irradiation 27Methotrexate 24Etoposide 20Cord Blood Stem Cell Transplantation 18Biopsy 18Methylprednisolone 16Specimen Handling 15Rituximab 14Magnetic Resonance Spectroscopy 13Alemtuzumab 12Stem Cell Transplantation 11Granulocyte Colony-Stimulating Factor 11Cytarabine 11sargramostim 9Sirolimus 9Prednisone 9Dexamethasone 9plerixafor 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Massage × Plasma cell × Clear all
NCT06063603 2025-09-18

ASCENT

Mayo Clinic

Phase NA Completed
51 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡